Search results for " Endocrine"

showing 10 items of 149 documents

Observatoire francophone des néoplasies endocriniennes multiples de type 1. Un outil du Groupe d'étude des Tumeurs Endocrines (GTE)

2007

Wermer's syndrome or Multiple Endocrine Neoplasia Type-1 (MEN1) is an autosomal dominant inherited disease, related to mutations in MEN1, an approximately 10-kb gene encoding menin, localized on chromosome 11q13. The Endocrine Tumor Group (GTE) has set up a MEN1 observatory of 1001 regularly followed MEN1 cases. This observatory aims at registering and evaluating MEN1 cases in a large cohort. Any new study on a particular unexplored aspect of the disease may be proposed by a physician to the GTE. This article describes the way to diagnose a new MEN1 case and to register it. Procedures for participating in a new study are presented. Some original results are quoted.

Gynecologycongenital hereditary and neonatal diseases and abnormalitiesendocrine systemmedicine.medical_specialtyPathologyEndocrine Tumorendocrine system diseasesbusiness.industryEndocrinology Diabetes and MetabolismGeneral Medicinemedicine.diseaseLarge cohortEndocrinologymedicineMEN1Inherited diseaseMultiple endocrine neoplasiabusinessAnnales d'Endocrinologie
researchProduct

Lacrimal glands herniation in patients with Graves’ Ophthalmopathy: an effective MRI-derived marker of disease activity

2017

Aims and objectives Methods and materials Results Conclusion Personal information References

InflammationHead and neckStaginggenetic structuresEndocrine disordersEyesMREyes Head and neck MR Diagnostic procedure Staging Endocrine disorders InflammationDiagnostic procedure
researchProduct

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?

2019

The interesting article by Yamabe et al.1 showed, using continuous glucose monitoring, that insulin degludec (I‐Deg) was associated with a high percentage of time with nocturnal hypoglycemia than with insulin glargine 300 U/mL (I‐G300; P = 0.02). However, we observe that some possible confounding factors might have influenced the results, such as differences in concomitant medications, use of the same titration protocol for both kinds of insulin or differences in glucose levels. This is also a recurrent problem in clinical trials, which sometime produce conflicting results. In fact, the study of Yamabe et al. is partly in agreement with some recently published clinical trials that gave diff…

Insulin degludecBlood Glucosemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentdiabetes insulin clinical trials hypoglicemiaInsulinsInsulin GlargineHypoglycemiaDiseases of the endocrine glands. Clinical endocrinologyInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsLetters to the EditorLetter to the EditorGlycated HemoglobinInsulin glarginebusiness.industryInsulinBlood Glucose Self-Monitoringnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseRC648-665HypoglycemiaClinical trialInsulin Long-ActingEndocrinologyDiabetes Mellitus Type 2businessmedicine.drug
researchProduct

Bisphenol-A impairs insulin action and up-regulates inflammatory pathways in human subcutaneous adipocytes and 3T3-L1 cells.

2013

Current evidence indicates that chemical pollutants may interfere with the homeostatic control of nutrient metabolism, thereby contributing to the increased prevalence of metabolic disorders. Bisphenol-A (BPA) is a lipophilic compound contained in plastic which is considered a candidate for impairing energy and glucose metabolism. We have investigated the impact of low doses of BPA on adipocyte metabolic functions. Human adipocytes derived from subcutaneous adipose tissue and differentiated 3T3-L1 cells were incubated with BPA, in order to evaluate the effect on glucose utilization, insulin sensitivity and cytokine secretion. Treatment with 1 nM BPA significantly inhibited insulin-stimulate…

Leptinmedicine.medical_treatmentAdipose tissuechemistry.chemical_compoundMice0302 clinical medicineAdipocyteAdipocytesInsulinPhosphorylation0303 health sciencesMultidisciplinaryPERSISTENT ORGANIC POLLUTANTS BODY-MASS INDEX METABOLIC SYNDROME ENVIRONMENTAL CONTAMINANTS CARDIOVASCULAR-DISEASE ENDOCRINE DISRUPTORS SERUM CONCENTRATIONS WIDESPREAD EXPOSURE PERINATAL EXPOSURE DIABETES-MELLITUSbiologyQRNF-kappa BCell Differentiation3. Good healthUp-RegulationAdipogenesisMedicinehormones hormone substitutes and hormone antagonistsResearch ArticleSignal TransductionSTAT3 Transcription Factormedicine.medical_specialtyendocrine systemScienceSubcutaneous FatDown-Regulation030209 endocrinology & metabolism03 medical and health sciencesDownregulation and upregulationPhenolsInternal medicine3T3-L1 CellsmedicineAnimalsHumansRNA MessengerBenzhydryl Compounds030304 developmental biologyInflammationurogenital systemInsulinJNK Mitogen-Activated Protein KinasesReceptor InsulinInsulin receptorEndocrinologyGlucosechemistry13. Climate actionbiology.proteinCytokine secretionGLUT4PloS one
researchProduct

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

2019

Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At…

Male0301 basic medicineOncologyPyridinesReceptor ErbB-2PhysiologyClinical BiochemistryPiperazineschemistry.chemical_compound0302 clinical medicineExemestaneAntineoplastic Combined Chemotherapy Protocolsadvanced breast cancer; hormonal therapy; endocrine resistance; palbociclib; real-world settingBreastAged 80 and overadvanced breast cancerhormonal therapyadvanced breast cancer hormonal therapy; endocrine resistance; palbociclib; real-world settingMiddle AgedTreatment OutcomeReceptors Estrogen030220 oncology & carcinogenesisToxicityFemaleReceptors Progesteronemedicine.drugAdultadvanced breast cancer hormonal therapy; endocrine resistance; palbociclib; real-world setting; Physiology; Clinical Biochemistry; Cell Biologymedicine.medical_specialtypalbociclibBreast NeoplasmsPalbociclibNeutropeniaadvanced breast cancer hormonal therapyDisease-Free Survivalendocrine resistance03 medical and health sciencesInternal medicinereal-world settingmedicineHumansAgedEverolimusSettore MED/06 - ONCOLOGIA MEDICAbusiness.industryCancerCell Biologymedicine.diseaseConfidence interval030104 developmental biologychemistryMED/06 - ONCOLOGIA MEDICAbusinessHormone
researchProduct

Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects

2020

Objective: In obese men, the increased expression of the aromatase enzyme in adipose tissue leads to high conversion of androgens to estrogens contributing to hypogonadotropic hypogonadism (HHG). Our objective is to evaluate efficacy and safety of weight loss (WL) plus aromatase inhibitor (AI) therapy in severely obese men with HHG. We hypothesize that AI+WL will be more effective as compared to WL alone in improving the hormonal profile, thus muscle strength and symptoms of HHG (primary outcomes), with no significant adverse effects on lean mass, metabolic profile, and bone mineral density (secondary outcomes).Design: Randomized double-blind placebo-controlled pilot trial.Methods: Twenty-t…

Male0301 basic medicineobesityBone densityEndocrinology Diabetes and MetabolismPilot Projectslcsh:Diseases of the endocrine glands. Clinical endocrinologyaromatase inhibitorsEndocrinology0302 clinical medicineBone DensityWeight lossMedicineTestosteroneTestosteroneBone mineralEstradiolMiddle AgedPrognosisClinical TrialAndrogensMetabolomemedicine.symptombone microarchitecturemedicine.drugAdultmedicine.medical_specialtyHormone Replacement Therapymedicine.drug_classAnastrozole030209 endocrinology & metabolismsex hormonesBone and Bones03 medical and health sciencesDouble-Blind MethodHypogonadotropic hypogonadismInternal medicineWeight LossHumanshypogonadismMuscle StrengthAgedbody compositionlcsh:RC648-665Aromatase inhibitorbusiness.industrymedicine.disease030104 developmental biologyEndocrinologyLean body massbusinessBiomarkersFollow-Up StudiesFrontiers in Endocrinology
researchProduct

European disparities in malignant digestive endocrine tumours survival.

2009

The aim of this study was to report on malignant digestive endocrine tumours (MDET) prognosis in several European countries. We analysed survival data from 19 cancer registries in 12 European countries on 3,715 MDET diagnosed between 1985 and 1994. The overall 5-year survival rate was 47.5%. It was 58.1% for differentiated MDET and 8.1% for small-cell MDET (p < 0.001), 55.9% for patients under 65 and 37.0% for older patients. Survival rates for small intestinal and colorectal were higher than for the other sites. The 5-year relative survival rates were 60.3% in Northern Europe, 53.6% in Western Continental Europe, 42.5% in the UK, 37.6% in Eastern Europe (p < 0.001). Among well-differentiat…

MaleCancer Researchmedicine.medical_specialtyPathologyGlucagonomaDigestive System NeoplasmsGastroenterologydigestive endocrine tumours survivalInternal medicineEndocrine Gland NeoplasmsmedicineHumansCarcinoid tumourRegistriesSurvival rateAgedNeoplasm StagingGastrinomaRelative survivalbusiness.industryAbsolute risk reductionCancerMiddle Agedmedicine.diseasePrognosisCancer registryEuropeSurvival RateOncologyFemalebusinessInternational journal of cancer
researchProduct

Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors2 Centimeters.

2019

Abstract Purpose Pancreatic neuroendocrine tumors (pNETs) are frequent in multiple endocrine neoplasia type 1 (MEN1) syndrome. They are usually not surgically treated unless larger than 1 to 2 cm or a growth rate &amp;gt; 0.5 cm per year. Somatostatin analogues represent one of the main therapeutic options in pNETs, but they have never been prospectively investigated in MEN1-related pNETs. The aim of this study was to prospectively evaluate the effectiveness of lanreotide in patients with MEN1-related pNETs &amp;lt; 2 cm. Methods MEN1 patients with 1 or more pNETs &amp;lt; 2 cm of maximal diameter were considered. Study design was prospective observational, comparing patients treated with l…

MaleEndocrinology Diabetes and MetabolismClinical BiochemistryNeuroendocrine tumorsLanreotideBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyactive surveillance lanreotide MEN1 pancreatic neuroendocrine tumors somatostatin analoguesProspective StudiesProspective cohort studyMultiple endocrine neoplasiasomatostatin analoguesMiddle AgedPrognosisTumor BurdenNeuroendocrine TumorsSomatostatinMEN1Disease ProgressionFemalelanreotideSomatostatinAdultmedicine.medical_specialtyAntineoplastic Agentspancreatic neuroendocrine tumorPeptides CyclicYoung AdultInternal medicinemedicineMultiple Endocrine Neoplasia Type 1HumansMEN1Watchful WaitingAgedCentimeterpancreatic neuroendocrine tumorsbusiness.industryBiochemistry (medical)active surveillancemedicine.diseasePancreatic NeoplasmsEndocrinologychemistryactive surveillance; lanreotide; MEN1; pancreatic neuroendocrine tumors; somatostatin analoguesTumor progressionCase-Control StudiesbusinessFollow-Up StudiesThe Journal of clinical endocrinology and metabolism
researchProduct

Effects of a weight management program delivered by social media on weight and metabolic syndrome risk factors in overweight and obese adults: A rand…

2017

Author(s): Jane, Monica; Hagger, Martin; Foster, Jonathan; Ho, Suleen; Kane, Robert; Pal, Sebely | Abstract: IntroductionThe aim of this project was to evaluate the effectiveness of using social media to augment the delivery of, and provide support for, a weight management program delivered to overweight and obese individuals during a twenty four week intervention.MethodsParticipants randomly divided into either one of two intervention groups or a control group. The two intervention groups were instructed to follow identical weight-management program. One group received the program within a Facebook group, along with a support network with the group, and the other intervention group receive…

MaleFacebookPGHealth Behaviorphysical activitySocial ScienceslipiditCardiovascularweight controlravitsemussuosituksetBiochemistrylaw.inventionBody Mass Index0302 clinical medicine7.1 Individual care needsSociologyWeight managementPublic and Occupational Healthlcsh:Sciencemetabolinen oireyhtymäta515Cancerblood pressureSocial Communicationylipainota3141LipidsWaist CircumferenceNetwork Analysisinsulinmedicine.medical_specialtyClinical Trials and Supportive Activitiesinsuliini03 medical and health sciencesSocial supportClinical ResearchHumansvertaisryhmätExerciseLife Styledietary guidelines6.7 Physicalpamphlet groupPreventionlcsh:RBiology and Life SciencesSocial SupportPhysical Activitymedicine.diseaseObesityCommunicationsverenpainelcsh:QManagement of diseases and conditionsBody mass indexSocial MediaPhysiologylcsh:MedicineOverweightOral and gastrointestinalFatsRandomized controlled trialWeight losslawBehavior TherapyRisk FactorsMedicine and Health Sciencesblood glucose030212 general & internal medicinepainoindeksita315Metabolic SyndromeMultidisciplinaryCGMiddle AgedStrokeSelf-Help GroupsTreatment OutcomeSocial NetworksPhysiological ParametersFemalemedicine.symptomResearch ArticleAdultComputer and Information SciencesGeneral Science & Technologysosiaalinen media030209 endocrinology & metabolismpainonhallintaBMIBehavioral and Social ScienceWeight LossmedicineObesityMetabolic and endocrineNutritionpeer groupsbusiness.industryBody WeightEvaluation of treatments and therapeutic interventionsOverweightDietLean body massPhysical therapybusinessPLoS ONE
researchProduct

International Physical Activity and Built Environment Study of Adolescents : IPEN Adolescent design, protocol and measures

2021

IntroductionOnly international studies can provide the full variability of built environments and accurately estimate effect sizes of relations between contrasting environments and health-related outcomes. The aims of the International Physical Activity and Environment Study of Adolescents (IPEN Adolescent) are to estimate the strength, shape and generalisability of associations of the community environment (geographic information systems (GIS)-based and self-reported) with physical activity and sedentary behaviour (accelerometer-measured and self-reported) and weight status (normal/overweight/obese).Methods and analysisThe IPEN Adolescent observational, cross-sectional, multicountry study …

MaleNEIGHBORHOOD ENVIRONMENTstatistics & research methodsWalkingOverweightCardiovascularOral and gastrointestinal0302 clinical medicineresearch methodsBelgiumResidence CharacteristicsInformed assentResearch MethodsMedicine and Health SciencesMedicineSOCIOECONOMIC-STATUS030212 general & internal medicine1506IsraelBuilt EnvironmentAetiologyChildBuilt environmentCzech RepublicCancerPediatricBangladeshpublic healthSEDENTARY BEHAVIORGeneral MedicineStrokeYOUTHWalkabilityRELIABILITYPublic Health and Health ServicesHong KongFemaleepidemiologySCHOOL-AGED CHILDRENHEALTHPSYCHOSOCIAL FACTORSmedicine.symptomsocial and economic factorsBrazilPediatric Research InitiativeAdolescentInternational studiesClinical SciencesNigeriaIndiapreventive medicine03 medical and health sciencesYoung Adult2.3 PsychologicalEnvironmental healthHumansObesitySocioeconomic statusExerciseMetabolic and endocrineNutritionOBJECTIVE ASSESSMENTWALKABILITY SCALEOther Medical and Health SciencesPortugalbusiness.industry1730PreventionMalaysiaAustralia030229 sport sciencesCross-Sectional StudiesSpainSurvey data collectionObservational studyEnvironment Designstatistics &ampbusinessNew Zealand
researchProduct